3-Oxo-5-alpha-Steroid 4-Dehydrogenase
"3-Oxo-5-alpha-Steroid 4-Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the reduction of TESTOSTERONE to 5-ALPHA DIHYDROTESTOSTERONE.
| Descriptor ID |
D013741
|
| MeSH Number(s) |
D08.811.682.660.465
|
| Concept/Terms |
3-Oxo-5-alpha-Steroid 4-Dehydrogenase- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase
- 3-oxo-5alpha-Steroid 4-Dehydrogenase (NADP+)
- Steroid delta-4-5-alpha Reductase
- Reductase, Steroid delta-4-5-alpha
- Steroid delta 4 5 alpha Reductase
- delta-4-5-alpha Reductase, Steroid
- Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase
- Testosterone delta-4-5-alpha-Reductase
- Testosterone delta 4 5 alpha Reductase
- delta-4-5-alpha-Reductase, Testosterone
- 3-Keto-5-alpha-Steroid delta-4-Dehydrogenase
- 3 Keto 5 alpha Steroid delta 4 Dehydrogenase
- delta-4-Dehydrogenase, 3-Keto-5-alpha-Steroid
- 4-Ene-3-Oxosteroid-5alpha-Reductase
- 4 Ene 3 Oxosteroid 5alpha Reductase
- 4-Ene-5-alpha-Reductase
- 4 Ene 5 alpha Reductase
- 5-alpha-Reductase, Testosterone
- 5 alpha Reductase, Testosterone
- delta(4)-3-Ketosteroid-5alpha-Reductase
- NADH-5-alpha-Reductase
- NADH 5 alpha Reductase
- NADPH delta(4)-3-Ketosteroid 5 alpha-Oxidoreductase
- Steroid 5-alpha-Reductase
- 5-alpha-Reductase, Steroid
- Steroid 5 alpha Reductase
- Steroid 5Alpha Reductase
- 5Alpha Reductase, Steroid
- Reductase, Steroid 5Alpha
- 3-oxo-5 alpha-Steroid 4-Dehydrogenase (NADP+)
- delta 4-3-keto Steroid 5 alpha-Oxidoreductase
- delta 4 3 keto Steroid 5 alpha Oxidoreductase
- delta4-3-ketosteroid 5alpha-Oxidoreductase
- 5alpha-Oxidoreductase, delta4-3-ketosteroid
- delta4 3 ketosteroid 5alpha Oxidoreductase
|
Below are MeSH descriptors whose meaning is more general than "3-Oxo-5-alpha-Steroid 4-Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "3-Oxo-5-alpha-Steroid 4-Dehydrogenase".
This graph shows the total number of publications written about "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" by people in this website by year, and whether "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" by people in Profiles.
-
Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Dec 01; 31(12).
-
Structure of human steroid 5a-reductase 2 with the anti-androgen drug finasteride. Nat Commun. 2020 10 27; 11(1):5430.
-
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr Opin Urol. 2018 Jan; 28(1):42-45.
-
SRD5A3-CDG: Expanding the phenotype of a congenital disorder of glycosylation with emphasis on adult onset features. Am J Med Genet A. 2016 12; 170(12):3165-3171.
-
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Prostate. 2015 Nov; 75(15):1790-801.
-
Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5a-dihydroprogesterone. Proc Natl Acad Sci U S A. 2014 Mar 04; 111(9):3365-70.
-
5a-reductase type 3 enzyme in benign and malignant prostate. Prostate. 2014 Feb; 74(3):235-49.
-
GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell. 2013 Jul 08; 24(1):11-3.
-
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012 Dec 01; 72(23):6142-52.
-
Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840.